Biocon Biologics secures US FDA approval to commercialise YESINTEK

BL Bengaluru Bureau Updated - December 01, 2024 at 07:46 PM.

The biosimilar drug will be used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis

Biocon Biologics, a subsidiary of Biocon Ltd, secured US Food and Drug Administration (FDA) approval to commercialise YESINTEK, a biosimilar.

The biosimilar drug will be used for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.

The company, which has entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively referred to as Janssen), plans to commercialise the drug by February 22, 2025.

Published on December 1, 2024 14:16
Tags

This is a Premium article available exclusively to our subscribers.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.

Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
If you're already a subscriber
Access just this article

You have reached your free article limit.
Subscribe now to and get well-researched and unbiased insights on the Stock market, Economy, Commodities and more...

Subscribe
or read this article by Downloading TheHindu Businessline News app
If you're already a subscriber
Access just this article

TheHindu Businessline operates by its editorial values to provide you quality journalism.

Support our reporting.
Subscribe
This is your last free article.
to read unlimited content from TheHindu Businessline
Subscribe
Stay updated on Markets,Economy, Agri & more.
Get TheHindu Businessline News App on
Recommended Articles